Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T.
Krafft U, et al. Among authors: szucs m.
Urol Oncol. 2019 Nov;37(11):810.e7-810.e15. doi: 10.1016/j.urolonc.2019.04.015. Epub 2019 Apr 30.
Urol Oncol. 2019.
PMID: 31053526